Alterity locks in underwriting for up to A$7.96M options raise

What's the deal? Alterity TherapeuticsDealroom has a profile for this one. Try Dealroom → has secured an underwriting agreement with MST Financial ServicesDealroom has a profile for this one. Try Dealroom → to support the exercise of up to 8.4 million ATHO listed options, a post-IPO equity raise expected to bring in between A$4.2 million and A$7.96 million before costs. MST FinancialDealroom has a profile for this one. Try Dealroom → will act as sole underwriter, backed by sub-underwriters under customary conditions and termination rights.

Why now? The ATHO options expire on August 31, 2026, and the underwriting is designed to secure funding ahead of that deadline. The final amount depends on the level of optionholder participation.

What's the endgame? Alterity is a biotechnology company developing disease-modifying treatments for neurodegenerative disorders, with a focus on Multiple System Atrophy (MSA). The capital will strengthen its balance sheet as it advances lead candidate ATH434 toward a planned Phase 3 pivotal trial in MSA, alongside general working capital needs.

The details: Listed on both the ASX and NASDAQ, Alterity uses its dual-market presence to access global capital. It currently carries a market capitalisation of A$114.5 million, and its most recent analyst rating is a Buy with a A$0.95 price target.

The signal: For a clinical-stage biotech, tapping existing options rather than a fresh placement offers a low-friction path to funding a costly Phase 3 program. The move underscores how late-stage drug developers lean on flexible capital structures to bridge toward pivotal trials.

Image credit: Generated with Gemini